Clinical Trial Update: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ipilimumab with GM-CSF immunotherapy for prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leukine (sargramostim)
• Yervoy (ipilimumab)

Snippet

Sponsor: Lawrence Fong | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN